“At the time, not everyone thought mAbs would be accepted,” said Melissa Elder, analyst for Kalorama Information. “Now they are thriving.’
As covered in their report, Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition, although the therapeutic vaccine market has experienced a range of setbacks and disappointments, technological evolution should ultimately enable therapeutic vaccines to make similar commercial breakthroughs as monoclonal antibodies. Scientists may be able to develop improved vaccines from a more complete understanding of the interactions between the immune system and cancer cells.
A new wave of 'off-the-shelf' generalized vaccines driven by genomic advances promise to remedy the commercial drawbacks of early personalized vaccines. As clinical experience mounts, new antigen delivery technologies appear and combination vaccines gain favor, the prospect of new non-toxic therapies for cancer and HIV gets closer to being reality.
More information on cancer vaccines, including potential products and forecasts for each category of cancer, can be found at: http://www.kaloramainformation.com/
# # #
About Kalorama Information
Kalorama Information (www.kaloramainformation.com)
Please direct all media inquiries to: